Clinical Trial Update: ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination of ASTX727 (cedazuridine + decitabine) and retifanlimab-dlwr for advanced Merkel cell carcinoma after progre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• retifanlimab-dlwr (retifanlimab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING